spbmedicalrecordsНовые Санкт-Петербургские врачебные ведомостиNew St. Petersburg Medical Records1609-2201Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова10.24884/1609-2201-2024-103-4-20-25spbmedicalrecords-40Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWSУровень мочевой кислоты как фактор риска неблагоприятного течения ХОБЛ и острого коронарного синдрома (ОКС)Uric acid level as a risk factor for the adverse course of COPD and acute coronary syndrome (ACS)https://orcid.org/0000-0003-4690-7655БручкусЕ. А.BruchkusE. A.

Бручкус Елена Анатольевна - врач высшей категории, заведующая кардиологическим отделением № 2 НИИ ревматологии и аллергологии НКИЦ.

Санкт-Петербург

Elena A. Bruchkus - physician of the highest category, head of the Cardiology Department No. 2 of the Research Institute of Rheumatology and Allergology.

Saint Petersburg

bruklen@list.ruhttps://orcid.org/0000-0003-4177-3264КуликВ. В.KulikV. V.

Кулик Владислав Витальевич - врач общей практики, ассистент кафедры общей врачебной практики (семейной медицины).

197022, Санкт-Петербург, ул. Льва Толстого, д. 6‒8

Vladislav V. Kulik - general practitioner, assistant of the Department of General Medical Practice (Family Medicine).

6‒8, L’va Tolstogo str., Saint Petersburg, 197022

vladislav.kulik.1996@mail.ruhttps://orcid.org/0000-0002-7848-8144КирпичниковС. И.KirpichnikovS. I.

Кирпичников Сергей Игоревич - врач общей практики, ассистент кафедры общей врачебной практики (семейной медицины).

Санкт-Петербург

Sergey I. Kirpichnikov - general practitioner, assistant of the Department of General Medical Practice (Family Medicine).

Saint Petersburg

sergvma@list.ruhttps://orcid.org/0000-0002-6457-5044ШапороваН. Л.ShaporovaN. L.

Шапорова Наталия Леонидовна - доктор медицинских наук, профессор, заведующая кафедрой общей врачебной практики (семейной медицины).

Санкт-Петербург

Natalia L. Shaporova - Dr. of Sci. (Med.), Professor, Head of the Department of General Medical Practice (Family Medicine).

St. Petersburg

shapnl@mail.ruПервый Санкт-Петербургский государственный медицинский университет имени академика И.П. ПавловаРоссияPavlov UniversityRussian Federation202418032025042025Copyright © Бручкус Е.А., Кулик В.В., Кирпичников С.И., Шапорова Н.Л., 20252025Бручкус Е.А., Кулик В.В., Кирпичников С.И., Шапорова Н.Л.Bruchkus E.A., Kulik V.V., Kirpichnikov S.I., Shaporova N.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.docved.ru/jour/article/view/40

В статье приведены современные данные о влиянии повышенного уровня мочевой кислоты на течение и прогноз таких значимых заболеваний, как острый коронарный синдром (ОКС) и хроническая обструктивная болезнь легких (ХОБЛ). Авторами убедительно показано, что гиперурикемия (ГУ) связана с более высокой смертностью и большей частотой сердечно-сосудистых событий после ОКС, а также значительно ухудшает течение ХОБЛ. Таким образом, уровень мочевой кислоты может рассматриваться в качестве маркера прогноза течения и риска прогрессирования данных заболеваний, что с учетом доступности его определения представляет значительный интерес для практической медицины.

The article presents current data on the effect of elevated uric acid levels on the course and prognosis of such significant diseases as acute coronary syndrome (ACS) and chronic obstructive pulmonary disease (COPD). The authors have convincingly shown that hyperuricemia (HY) is associated with higher mortality and a higher frequency of cardiovascular events after ACS, as well as significantly worsens the course of COPD. Thus, the level of uric acid can be considered as a marker for the prognosis of the course and risk of progression of these diseases, considering of its availability, is of interest for practical medicine.

мочевая кислотагиперурикемияхроническая обструктивная болезнь легких (ХОБЛ)острый коронарный синдром (ОКС)uric acidhyperuricemiachronic obstructive pulmonary disease (COPD)acute coronary syndrome (ACS)ReferencesMaloberti A., Giannattasio C., Bombelli M. et al. Hyperuricemia and risk of cardiovascular outcomes: the experience of the URRAH (Uric Acid Right for Heart Health) project // High Blood Pressure and Cardiovascular Prevention. 2020. Vol. 27, № 2. P. 121–128. https://doi.org/10.1007/s40292-020-00368-z.Maloberti A., Giannattasio C., Bombelli M. et al. Hyperuricemia and risk of cardiovascular outcomes: the experience of the URRAH (Uric Acid Right for Heart Health) project. High Blood Pressure and Cardiovascular Prevention. 2020;27(2):121–128. https://doi.org/10.1007/s40292-020-00368-z.Шальнова С. А., Деев А. Д., Артамонова Г. В. и др. Гиперурикемия и ее корреляты в российской популяции (результаты эпидемиологического исследования эссе-рф) // Рациональная фармакотерапия в кардиологии. 2014. Т. 10, № 2. С. 153–159. https://doi.org/10.20996/1819-6446-2014-10-2-153-159.Shalnova S. A., Deev A. D., Artamonov G. V. et al. Hyperuricemia and its correlates in the Russian population (results of esse-rf epidemiological study). Rational Pharmacotherapy in Cardiology. 2014;10(2):153–159. (In Russ.). https://doi.org/10.20996/1819-6446-2014-10-2-153-159.Головач И. Ю., Егудина Е. Д., Тер-Вартаньян С. Х. Бессимптомная гиперурикемия: тайные взаимосвязи, невидимые эффекты и потенциальные осложнения // Научнопрактическая ревматология. 2020. Т. 58, № 6. С. 725–733. https://doi.org/10.47360/1995-4484-2020-725-733.Golovach I. Yu., Yehudina Y. D., Ter-Vartanian S. Kh. Asymptomatic hyperuricemia: secret relationships, invisible effects and potential complications. Rheumatology Science and Practice. 2020;58(6):725–733. (In Russ.). https://doi.org/10.47360/1995-4484-2020-725-733.Либов И. А., Моисеева Ю. Н., Комарова А. Г. Гиперурикемия как фактор риска сердечно-сосудистых осложнений у пациентов с артериальной гипертонией // Российский кардиологический журнал. 2022. Т. 27, № 9. С. 5194. https://doi.org/10.15829/1560-4071-2022-5194.Libov I. A., Moiseeva Yu. N., Komarova A. G. Hyperuricemia as a risk factor for cardiovascular events in hypertensive patients. Russian Journal of Cardiology. 2022;27(9):5194. (In Russ.). https://doi.org/10.15829/1560-4071-2022-5194.Freilich M., Arredondo A., Zonnoor S. L., McFarlane I. M. Elevated serum uric acid and cardiovascular disease: a review and potential therapeutic interventions // Cureus. 2022. Vol. 14, № 3. P. e23582. https://doi.org/10.7759/cureus.Freilich M., Arredondo A., Zonnoor S. L., McFarlane I. M. Elevated serum uric acid and cardiovascular disease: a review and potential therapeutic interventions. Cureus. 2022;14(3):e23582. https://doi.org/10.7759/cureus.Grassi G., Vanoli J., Facchetti R., Mancia G. Uric acid, hypertensive phenotypes, and organ damage: data from the Pamela study // Curr Hypertens Rep. 2022. Vol. 24, № 2. P. 29–35. https://doi.org/10.1007/s11906-022-01174-9.Grassi G., Vanoli J., Facchetti R., Mancia G. Uric acid, hypertensive phenotypes, and organ damage: data from the Pamela study. Curr Hypertens Rep. 2022;24(2):29–35. https://doi.org/10.1007/s11906-022-01174-9.Li M., Hu X., Fan Y. et al. Hyperuricemia and the risk for coronary heart disease morbidity and mortality: a systematic review and dose-response meta-analysis //sci Rep. 2016. Vol. 6. P. 19520. https://doi.org/10.1038/srep19520.Li M., Hu X., Fan Y. et al. Hyperuricemia and the risk for coronary heart disease morbidity and mortality: a systematic review and dose-response meta-analysis. Sci Rep. 2016;6:19520. https://doi.org/10.1038/srep19520.Gao Z., Shi H., Xu W. et al. Hyperuricemia increases the risk of atrial fibrillation: a systematic review and meta-analysis //int J Endocrinol. 2022. Vol. 2022. P. 8172639. https://doi.org/10.1155/2022/8172639.Gao Z., Shi H., Xu W. et al. Hyperuricemia increases the risk of atrial fibrillation: a systematic review and meta-analysis. Int J Endocrinol. 2022;2022:8172639. https://doi.org/10.1155/2022/8172639.Raya-Cano E., Vaquero-Abellán M., Molina-Luque R. et al. Association between metabolic syndrome and uric acid: a systematic review and meta-analysis //sci Rep. 2022. Vol. 12, № 1. P. 18412. https://doi.org/10.1038/s41598-022-22025-2.Raya-Cano E., Vaquero-Abellán M., Molina-Luque R. et al. Association between metabolic syndrome and uric acid: a systematic review and meta-analysis. Sci Rep. 2022;12(1):18412. https://doi.org/10.1038/s41598-022-22025-2.Gonçalves D. L. N., Moreira T. R., da Silva L. S. A systematic review and meta-analysis of the association between uric acid levels and chronic kidney disease //sci Rep. 2022. Vol. 12, № 1. P. 6251. https://doi.org/10.1038/s41598-022-10118-x.Gonçalves D. L. N., Moreira T. R., da Silva L. S. A systematic review and meta-analysis of the association between uric acid levels and chronic kidney disease. Sci Rep. 2022;12(1):6251. https://doi.org/10.1038/s41598-022-10118-x.Borghi C., Agabiti-Rosei E., Johnson R. J. et al. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease // Eur J Intern Med. 2020. Vol. 80. P. 1–11. https://doi.org/10.1016/j.ejim.2020.07.006.Borghi C., Agabiti-Rosei E., Johnson R. J. et al. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. Eur J Intern Med. 2020;80:1–11. https://doi.org/10.1016/j.ejim.2020.07.006.Kikuchi A., Kawamoto R., Ninomiya D., Kumagi T. Hyperuricemia is associated with all-cause mortality among males and females: findings from a study on Japanese community-dwelling individuals // Metabolism Open. 2022. Vol. 14. P. 100186. https://doi.org/10.1016/j.metop.2022.100186.Kikuchi A., Kawamoto R., Ninomiya D., Kumagi T. Hyperuricemia is associated with all-cause mortality among males and females: findings from a study on Japanese community-dwelling individuals. Metabolism Open. 2022;14:100186. https://doi.org/10.1016/j.metop.2022.100186.Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2023. URL: https://goldcopd.org/ (accessed: 20.12.24).Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2023. URL: https://goldcopd.org/ (accessed: 20.12.24).Masannagari P., Chaitra H. B., Choudhary A., Rajashekaraiah V. Influence of uric acid on erythrocytes subjected to H₂O₂-induced oxidative stress // Appl In Vitro Toxicol. 2023. Vol. 9, № 2. P. 37–43. https://doi.org/10.1089/aivt.2023.0001.Masannagari P., Chaitra H. B., Choudhary A., Rajashekaraiah V. Influence of uric acid on erythrocytes subjected to H₂O₂-induced oxidative stress. Appl In Vitro Toxicol. 2023;9(2):37–43. https://doi.org/10.1089/aivt.2023.0001.Ma P., Zhao M., Li Y. et al. The protective effects of uric acid against myocardial ischemia via the Nrf2 pathway // Eur J Pharmacol. 2023. Vol. 959. P. 176062. https://doi.org/10.1016/j.ejphar.2023.176062.Ma P., Zhao M., Li Y. et al. The protective effects of uric acid against myocardial ischemia via the Nrf2 pathway. Eur J Pharmacol. 2023;959: 176062. https://doi.org/10.1016/j.ejphar.2023.176062.Галунска Б., Паскалев Д., Янкова Т., Чанкова П. Двуликий Янус биохимии: мочевая кислота – оксидант или антиоксидант? // Нефрология. 2004. Т. 8, № 4. С. 25–31. URL: https://cyberleninka.ru/article/n/dvulikiy-yanus-biohimii-mochevaya-kislota-oksidant-ili-antioksidant (дата обращения: 20.12.24).Galunska B., Paskalev D., Yankova T., Chankova P. The biochemical Ianus: uric acid oxidant or antioxidant? Nephrology. 2004;8(4):25–31. URL: https://cyberleninka.ru/article/n/dvulikiy-yanus-biohimii-mochevaya-kislota-oksidant-ili-antioksidant (accessed: 20.12.24).Kurajoh M., Fukumoto S., Yoshida S. et al. Uric acid shown to contribute to increased oxidative stress level independent of xanthine oxidoreductase activity in MedCity21 health examination registry //sci Rep. 2021. Vol. 11, № 1. P. 7378. https://doi.org/10.1038/s41598-021-86962-0.Kurajoh M., Fukumoto S., Yoshida S. et al. Uric acid shown to contribute to increased oxidative stress level independent of xanthine oxidoreductase activity in MedCity21 health examination registry. Sci Rep. 2021;11(1):7378. https://doi.org/10.1038/s41598-021-86962-0Zhang M., Cui R., Zhou Y. et al. Uric acid accumulation in the kidney triggers mast cell degranulation and aggravates renal oxidative stress // Toxicology. 2022. Vol. 483. P. 153387. https://doi.org/10.1016/j.tox.2022.153387.Zhang M., Cui R., Zhou Y. et al. Uric acid accumulation in the kidney triggers mast cell degranulation and aggravates renal oxidative stress. Toxicology. 2022;483:153387. https://doi.org/10.1016/j.tox.2022.153387Kahnert K., Alter P., Welte T. et al. Uric acid, lung function, physical capacity and exacerbation frequency in patients with COPD: a multi-dimensional approach // Respir Res. 2018. Vol. 19. P. 110. https://doi.org/10.1186/s12931-018-0815-y.Kahnert K., Alter P., Welte T. et al. Uric acid, lung function, physical capacity and exacerbation frequency in patients with COPD: a multi-dimensional approach. Respir Res. 2018;19:110. https://doi.org/10.1186/s12931-018-0815-y.Embarak S., Sileem A. E., Abdrabboh M., Mokhtar A. Serum uric acid as a biomarker for prediction of outcomes of patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease // Egypt J Bronchol. 2014. Vol. 8. P. 115–120. https://doi.org/10.4103/1687-8426.145703.Embarak S., Sileem A. E., Abdrabboh M., Mokhtar A. Serum uric acid as a biomarker for prediction of outcomes of patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease. Egypt J Bronchol. 2014;8:115–120. https://doi.org/10.4103/16878426.145703.Bartziokas K., Papaioannou A. I., Loukides S. et al. Serum uric acid as a predictor of mortality and future exacerbations of COPD // Eur Respir J. 2014. Vol. 43, № 1. P. 43–53. https://doi.org/10.1183/09031936.00209212.Bartziokas K., Papaioannou A. I., Loukides S. et al. Serum uric acid as a predictor of mortality and future exacerbations of COPD. Eur Respir J. 2014;43(1):43–53. https://doi.org/10.1183/09031936.00209212.Kobylecki C. J., Vedel-Krogh S., Afzal S. et al. Plasma urate, lung function and chronic obstructive pulmonary disease: a Mendelian randomisation study in 114 979 individuals from the general population // Thorax. 2018. Vol. 73. P. 748–757. https: //dx.doi.org/10.1136/thoraxjnl-2017-210273.Kobylecki C. J., Vedel-Krogh S., Afzal S. et al. Plasma urate, lung function and chronic obstructive pulmonary disease: a Mendelian randomisation study in 114 979 individuals from the general population. Thorax. 2018;73:748–757. https://dx.doi.org/10.1136/thoraxjnl-2017-210273.Yang H., Wang Z., Xiao S. et al. Association between serum uric acid and lung function in people with and without chronic obstructive pulmonary disease //int J Chron Obstruct Pulmon Dis. 2022. Vol. 2022. P. 1069–1080. https://dx.doi.org/10.2147/COPD.S356797.Yang H., Wang Z., Xiao S. et al. Association between serum uric acid and lung function in people with and without chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2022;2022:1069– 1080. https://dx.doi.org/10.2147/COPD.S356797.Sahana K., Sivaranjani H. Uric acid: a mirror to the lungs in COPD // J Assoc Physicians India. 2022. Vol. 70, № 4. P. 11–2. PMID: 35443464.Sahana K., Sivaranjani H. Uric acid: a mirror to the lungs in COPD. J Assoc Physicians India. 2022;70(4):11–2. PMID: 35443464.Sharaf El Din U. A., Salem M. M., Abdulazim D. O. Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: a review // J Adv Res. 2017. Vol. 8, № 5. P. 537–548. https://dx.doi.org/10.1016/j.jare.2016.11.004.Sharaf El Din U. A., Salem M. M., Abdulazim D. O. Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: a review. J Adv Res. 2017;8(5):537–548. https://dx.doi.org/10.1016/j.jare.2016.11.004.Jayashankar C. A., Andrews H. P., Vijayasarathi et al. Serum uric acid and low-density lipoprotein cholesterol levels are independent predictors of coronary artery disease in Asian Indian patients with type 2 diabetes mellitus // J Nat Sci Biol Med. 2016. Vol. 7, № 2. P. 161–165. https://doi.org/10.4103/0976-9668.184703.Jayashankar C. A., Andrews H. P., Vijayasarathi et al. Serum uric acid and low-density lipoprotein cholesterol levels are independent predictors of coronary artery disease in Asian Indian patients with type 2 diabetes mellitus. J Nat Sci Biol Med. 2016;7(2):161–165. https://doi.org/10.4103/0976-9668.184703.Tscharre M., Herman R., Rohla M. et al. Uric acid is associated with long-term adverse cardiovascular outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention // Atherosclerosis. 2018. Vol. 270. P. 173–179. https://dx.doi.org/10.1016/j.atherosclerosis.2018.02.003.Tscharre M., Herman R., Rohla M. et al. Uric acid is associated with long-term adverse cardiovascular outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Atherosclerosis. 2018;270:173–179. https://dx.doi.org/10.1016/j.atherosclerosis.2018.02.003.Magnoni M., Berteotti M., Ceriotti F. et al. Serum uric acid on admission predicts in-hospital mortality in patients with acute coronary syndrome //int J Cardiol. 2017. Vol. 240. P. 25–29. https://doi.org/10.1016/j.ijcard.2017.04.027.Magnoni M., Berteotti M., Ceriotti F. et al. Serum uric acid on admission predicts in-hospital mortality in patients with acute coronary syndrome. Int J Cardiol. 2017;240:25–29. https://doi.org/10.1016/j.ijcard.2017.04.027.Eckner D., Popp S., Wicklein S., Pauschinger M. Acute coronary syndrome in older people // Gerontol Geriatr. 2018. Vol. 51, № 4. P. 461–475. (In German) https://dx.doi.org/10.1007/s00391-018-1411-y.Eckner D., Popp S., Wicklein S., Pauschinger M. Acute coronary syndrome in older people. Z Gerontol Geriatr. 2018;51(4):461–475. (In German) https://dx.doi.org/10.1007/s00391-018-1411-y.Pagidipati N. J., Hess C. N., Clare R. M. et al. An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome // Am Heart J. 2017. Vol. 187. P. 53–61. https://doi.org/10.1016/j.ahj.2017.02.023.Pagidipati N. J., Hess C. N., Clare R. M. et al. An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome. Am Heart J. 2017;187:53–61. https://doi.org/10.1016/j.ahj.2017.02.023.Guo G., Huang Z., Wang S., Chen X. Sex differences in uric acid and NT-proBNP assessments during coronary severity // Medicine (Baltimore). 2020. Vol. 99, № 15. P. e19653. https://dx.doi.org/10.1097/MD.0000000000019653.Guo G., Huang Z., Wang S., Chen X. Sex differences in uric acid and NT-proBNP assessments during coronary severity. Medicine (Baltimore). 2020;99(15):e19653. https://dx.doi.org/10.1097/MD.0000000000019653.Spahic E., Hasic S., Kiseljakovic E. et al. Positive correlation between uric acid and C-reactive protein serum level in healthy individuals and patients with acute coronary syndromes // Med Glas (Zenica). 2015. Vol. 12, № 2. P. 128–132. https://doi.org/10.17392/821.Spahic E., Hasic S., Kiseljakovic E. et al. Positive correlation between uric acid and C-reactive protein serum level in healthy individuals and patients with acute coronary syndromes. Med Glas (Zenica). 2015;12(2):128–132. https://doi.org/10.17392/821.Saito Y., Kitahara H., Nakayama T. et al. Relation of elevated serum uric acid level to endothelial dysfunction in patients with acute coronary syndrome // J Atheroscler Thromb. 2019. Vol. 26, № 4. P. 362–7. https://doi.org/10.5551/jat.45179.Saito Y., Kitahara H., Nakayama T. et al. Relation of elevated serum uric acid level to endothelial dysfunction in patients with acute coronary syndrome. J Atheroscler Thromb. 2019;26(4):362–7. https://doi.org/10.5551/jat.45179.Kobayashi N., Hata N., Tsurumi M. et al. Relation of coronary culprit lesion morphology determined by optical coherence tomography and cardiac outcomes to serum uric acid levels in patients with acute coronary syndrome // Am J Cardiol. 2018. Vol. 122, № 1. P. 17–25. https://dx.doi.org/10.1016/j.amjcard.2018.03.022.Kobayashi N., Hata N., Tsurumi M. et al. Relation of coronary culprit lesion morphology determined by optical coherence tomography and cardiac outcomes to serum uric acid levels in patients with acute coronary syndrome. Am J Cardiol. 2018;122(1):17–25. https://dx.doi.org/10.1016/j.amjcard.2018.03.022.Karim B., Nasution S. A., Wijaya I. P., Harimurti K. Hyperuricemia as a risk factor of major adverse cardiac events in patients with acute coronary syndrome: a retrospective cohort study // Acta Med Indones. 2015. Vol. 47, № 4. P. 320–5. PMID: 26932701.Karim B., Nasution S. A., Wijaya I. P., Harimurti K. Hyperuricemia as a risk factor of major adverse cardiac events in patients with acute coronary syndrome: a retrospective cohort study. Acta Med Indones. 2015;47(4):320–5. PMID: 26932701.Lopez-Pineda A., Cordero A., Carratala-Munuera C. et al. Hyperuricemia as a prognostic factor after acute coronary syndrome // Atherosclerosis. 2018. Vol. 269. P. 229–235. PMID: 29407598. https://dx.doi.org/10.1016/j.atherosclerosis.2018.01.017.Lopez-Pineda A., Cordero A., Carratala-Munuera C. et al. Hyperuricemia as a prognostic factor after acute coronary syndrome. Atherosclerosis. 2018;269:229–235. PMID: 29407598. https://dx.doi.org/10.1016/j.atherosclerosis.2018.01.017.Cuifang He, Peihuan Lin, Wenbin Liu, Kuifa Fang. The prognostic value of hyperuricemia in patients with acute coronary syndrome: a meta-analysis // Eur J Clin Invest. 2019. Vol. 49, № 4. P. e13074. PMID: 30701529. https://doi.org/10.1111/eci.13074.Cuifang He, Peihuan Lin, Wenbin Liu, Kuifa Fang. The prognostic value of hyperuricemia in patients with acute coronary syndrome: a meta-analysis. Eur J Clin Invest. 2019;49(4):e13074. PMID: 30701529. https://doi.org/10.1111/eci.13074.

The authors declare that there are no conflicts of interest present.